Nickname: take3pay2

Review: BMY is the buyer. They need to close the agreement with Imclone. They're losing money at this sales level. They have commmittments to spend a huge amount of money over development and marketing. Now that Amgen is in place, growth looks difficult and BMY badly needs full control. The agreement is the key. Remember: Icahn's in for a reason. He wouldn't have put those $250 million-plus if he didn't knew how to get out. He knew BMY wanted Imclone, that's why he got in.

Date reviewed: Jun 13, 2006 11:08 AM